niclosamide has been researched along with Amyotrophic Lateral Sclerosis in 3 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Importantly, niclosamide in vivo treatment of ALS-FUS mice reduces the expression of S100A4, α-SMA, and PDGFRβ in the spinal cord, as well as gliosis in central and peripheral nervous tissues, together with axonal impairment and displays beneficial effects on muscle atrophy, by promoting muscle regeneration and reducing fibrosis." | 8.02 | Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis. ( Apolloni, S; Cozzolino, M; D'Ambrosi, N; Lattante, S; Mammarella, E; Miele, C; Milani, M; Rossi, S; Sabatelli, M, 2021) |
| " Importantly, niclosamide in vivo treatment of ALS-FUS mice reduces the expression of S100A4, α-SMA, and PDGFRβ in the spinal cord, as well as gliosis in central and peripheral nervous tissues, together with axonal impairment and displays beneficial effects on muscle atrophy, by promoting muscle regeneration and reducing fibrosis." | 4.02 | Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis. ( Apolloni, S; Cozzolino, M; D'Ambrosi, N; Lattante, S; Mammarella, E; Miele, C; Milani, M; Rossi, S; Sabatelli, M, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Serrano, A | 1 |
| Apolloni, S | 2 |
| Rossi, S | 2 |
| Lattante, S | 2 |
| Sabatelli, M | 2 |
| Peric, M | 1 |
| Andjus, P | 1 |
| Michetti, F | 1 |
| Carrì, MT | 1 |
| Cozzolino, M | 2 |
| D'Ambrosi, N | 2 |
| Milani, M | 1 |
| Mammarella, E | 1 |
| Miele, C | 1 |
| Kato, Y | 1 |
| Sakamoto, K | 1 |
3 other studies available for niclosamide and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
The S100A4 Transcriptional Inhibitor Niclosamide Reduces Pro-Inflammatory and Migratory Phenotypes of Microglia: Implications for Amyotrophic Lateral Sclerosis.
Topics: Adult; Amyotrophic Lateral Sclerosis; Animals; Blotting, Western; Cell Movement; Cells, Cultured; El | 2019 |
Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Disease Models, Animal; Fibro | 2021 |
Niclosamide affects intracellular TDP-43 distribution in motor neurons, activates mitophagy, and attenuates morphological changes under stress.
Topics: Amyotrophic Lateral Sclerosis; DNA-Binding Proteins; Humans; Mitophagy; Motor Neurons; Niclosamide | 2021 |